AstraZeneca is transitioning 16,000 vehicles in its global fleet to battery-electric assets following the company's move to join the EV100.
AstraZeneca is the first pharmaceutical company to join the EV100, which is a global initiative by the Climate Group designed to bring together forward looking companies committed to accelerating the transition to electric vehicles. The 16,000 business vehicles span operations the U.S., Europe, and Japan, and aims to save more than 88,000 tons of carbon-dioxide emissions every year from 2030.
To support the shift to electric vehicles, AstraZeneca will also expand the charging infrastructure at its office sites, according to a release.
The pharmaceutical company laid out a strategy for its global EV end-of-year plan. At the end of 2019, it plans to have 120 EVs in the United Kingdom; 213 EVs in Spain; 245 EVs in France; and 230 EVs in Scandinavia.
AstraZeneca's EV fleet will soon be fully powered by renewable power as well, according to the company. Roughly 61% of its total electricity use sourced or generated from renewable sources.